Показано 0 из 0
Дата |
---|
18:21 |
02.05.2024 |
01.05.2024 |
30.04.2024 |
29.04.2024 |
26.04.2024 |
25.04.2024 |
24.04.2024 |
23.04.2024 |
22.04.2024 |
Bid | Ask |
Open |
Min | Max |
Last |
Legal close |
Avg |
Оборот |
Кол-во сделок |
---|---|---|---|---|---|---|---|
2.37
|
2.49
|
2.37
|
2.37
|
2.48
|
2.46
|
|
|
28 422.31
|
44.00
|
2.21
|
2.54
|
2.22
|
2.22
|
2.34
|
2.28
|
|
|
12 361.43
|
42.00
|
2.08
|
2.43
|
2.16
|
2.10
|
2.24
|
2.17
|
|
|
1 351.54
|
15.00
|
2.11
|
2.28
|
2.15
|
2.10
|
2.28
|
2.18
|
|
|
3 076.19
|
25.00
|
1.94
|
2.18
|
2.17
|
2.04
|
2.38
|
2.09
|
|
|
30 195.28
|
100.00
|
2.03
|
2.39
|
2.05
|
2.05
|
2.17
|
2.13
|
|
|
4 452.00
|
51.00
|
1.75
|
2.29
|
2.13
|
2.08
|
2.16
|
2.13
|
|
|
7 275.14
|
49.00
|
2.06
|
2.52
|
2.23
|
2.10
|
2.23
|
2.13
|
|
|
4 256.27
|
31.00
|
2.25
|
2.52
|
2.18
|
2.17
|
2.34
|
2.32
|
|
|
15 390.32
|
41.00
|
2.04
|
2.25
|
2.15
|
1.94
|
2.20
|
2.13
|
|
|
48 610.32
|
120.00
|
Immix Biopharma, Inc. operates as a clinical-stage biopharmaceutical company. The Company focuses on developing a novel class of tissue-specific therapeutics in oncology and inflammation to treat inflammatory bowel disease, including ulcerative colitis and crohn's diseases. Immix Biopharma serves customers in the United States.